IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

Published:2021-05 Issue:10289 Volume:397 Page:2060-2069
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ridker Paul M,Devalaraja Matt,Baeres Florian M M,Engelmann Mads D M,Hovingh G Kees,Ivkovic Milana,Lo Larry,Kling Douglas,Pergola Pablo,Raj Dominic,Libby Peter,Davidson Michael

Funder

Novo Nordisk AS

Publisher

Elsevier BV

Subject

General Medicine

Reference33 articles.

1. Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis;Ridker;Circ Res,2019

2. Antiinflammatory therapy with canakinumab for atherosclerotic disease;Ridker;N Engl J Med,2017

3. Efficacy and safety of low-dose colchicine after myocardial infarction;Tardif;N Engl J Med,2019

4. Colchicine in patients with chronic coronary disease;Nidorf;N Engl J Med,2020

5. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS);Ridker;Eur Heart J,2018

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive retrospect on biomarkers indicating vascular failure;Vascular Failure;2024-12-01

2. Prognostic significance of C-reactive protein-albumin-lymphocyte (CALLY) index after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction;International Immunopharmacology;2024-11

3. Pharmacological therapy targeting the immune response in atherosclerosis;International Immunopharmacology;2024-11

4. Inflammatory biomarkers and long-term outcome in young patients three months after a first myocardial infarction;Cytokine;2024-10

5. AIM2 Deficiency Alleviates Cardiac Inflammation and Hypertrophy in HFD/STZ-Induced Diabetic Mice by Inhibiting the NLRC4/IRF1 Signaling Pathway;Journal of Cardiovascular Translational Research;2024-09-04